The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $3.28

Today's change0.00 0.00%
Updated April 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $3.28

Today's change0.00 0.00%
Updated April 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc closed at (U.S.)$3.28.

Over the last five days, shares have gained 3.80%, but are down 19.61% for the last year to date. Shares have underperformed the S&P 500 by 68.52% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $3.28
  • High--
  • Low--
  • Bid / Ask(U.S.) $3.25 / (U.S.) $3.36
  • YTD % change-19.61%
  • Volume0
  • Average volume (10-day)1,387,458
  • Average volume (1-month)2,138,778
  • Average volume (3-month)3,099,223
  • 52-week range(U.S.) $2.83 to (U.S.) $7.51
  • Beta1.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.22
Updated April 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-106.41%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue61283421
Total other revenue--------
Total revenue61283421
Gross profit58273221
Total cost of revenue3121
Total operating expense88526451
Selling / general / administrative24182118
Research & development55324133
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)51----
Other operating expenses, total--------
Operating income-26-24-30-30
Interest income (expense), net non-operating-7-7-21-9
Gain (loss) on sale of assets--------
Other--------
Income before tax-34-30-51-39
Income after tax-34-30-51-39
Income tax, total--------
Net income-32-30-51-38
Total adjustments to net income--------
Net income before extra. items-32-30-51-38
Minority interest1000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-32-30-51-38
Inc. avail. to common incl. extra. items-32-30-51-38
Diluted net income-32-30-51-38
Dilution adjustment00----
Diluted weighted average shares130129126116
Diluted EPS excluding extraordinary itemsvalue per share-0.25-0.23-0.40-0.33
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.21-0.23-0.40-0.33